Brief: Zynerba Pharmaceuticals Announces Completion Of Enrollment In Phase 2 Trial Of Zygel
28/02/2022 12:48
Feb 28 (Reuters) - Zynerba Pharmaceuticals Inc ZYNE.O :
* ZYNERBA PHARMACEUTICALS ANNOUNCES COMPLETION OF ENROLLMENT
IN
PHASE 2 TRIAL OF ZYGEL™ IN 22Q11.2 DELETION SYNDROME
Source text for Eikon: ID:nGNX1PW2rT
Further company coverage: ZYNE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zynerba Pharmaceuticals
See all newsBrief: Harmony Biosciences Completes Acquisition Of Zynerba Pharmaceuticals
Brief: Harmony Biosciences Announces Extension Of Tender Offer To Acquire Zynerba Pharmaceuticals, Inc.
Brief: Zynerba Pharmaceuticals Presents Positive Data From Phase 2 Inspire Trial
U.S. RESEARCH ROUNDUP-Easterly Government Properties, Visa, Zynerba Pharmaceuticals
Zynerba Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary